Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis
Pooled result · Major adverse cardiovascular eventsResult — go to the resultRelative risk 0.87 95% CI 0.83–0.92Authors' conclusion
GLP-1RAs are associated with improved cardiovascular outcomes in patients with T2DM. These findings support current guideline recommendations and highlight their cardioprotective benefits beyond glycaemic control in patients with T2DM.
Study context
- Population
- Patients with type 2 diabetes mellitus (T2DM) in randomized controlled trials comparing GLP-1RAs with placebo
- Participants
- 83,004 patients20 randomized controlled trials (RCTs)
- Comparison
- GLP-1RAs compared to placebo
- Outcome
- Major adverse cardiovascular events
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
As reported in the abstract
Relative risk
0.87
95% CI 0.83–0.92
GLP-1RAsvs placebo
RR 0.87 (95% CI 0.83–0.92)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| All-cause death | 0.89 (0.84–0.93) | |
| Cardiovascular death | 0.88 (0.81–0.94) | |
| Myocardial infarction | 0.87 (0.79–0.96) | |
| Stroke | 0.88 (0.81–0.96) | |
| Composite renal outcome | 0.80 (0.73–0.88) | |
| Heart failure hospitalizationsTrend of reduction without reaching statistical significance | 0.93 (0.85–1.01) | |
| Coronary revascularizationTrend of reduction without reaching statistical significance | 0.87 (0.74–1.01) | |
| 0.512Relative risk (log scale) |
Original publication
Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. Published 16 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →